AR120859A1 - Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina - Google Patents

Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Info

Publication number
AR120859A1
AR120859A1 ARP200103597A ARP200103597A AR120859A1 AR 120859 A1 AR120859 A1 AR 120859A1 AR P200103597 A ARP200103597 A AR P200103597A AR P200103597 A ARP200103597 A AR P200103597A AR 120859 A1 AR120859 A1 AR 120859A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
integrine
inhibitors
combined treatment
liver diseases
Prior art date
Application number
ARP200103597A
Other languages
English (en)
Spanish (es)
Inventor
Kraig Anderson
Christopher Bailey
Avirup Bose
Jacob Cha
Nicole Cooper
Darren Finkelstein
Linda Greenbaum
Johannes Hull
Susan Kirkland
Katerina Leftheris
Maureen Reily
Peter Tarsa
Chinweike Ukomadu
Original Assignee
Novartis Ag
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Pliant Therapeutics Inc filed Critical Novartis Ag
Publication of AR120859A1 publication Critical patent/AR120859A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP200103597A 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina AR120859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
AR120859A1 true AR120859A1 (es) 2022-03-23

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103597A AR120859A1 (es) 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3509590A4 (en) * 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
RU2019110780A (ru) * 2016-09-14 2020-10-15 Новартис Аг Комбинация агонистов fxr
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Also Published As

Publication number Publication date
AU2020405182B2 (en) 2024-03-14
EP4076455A1 (en) 2022-10-26
CA3165000A1 (en) 2021-06-24
JP2023507387A (ja) 2023-02-22
AU2020405182A1 (en) 2022-07-07
IL293895A (en) 2022-08-01
KR20220121838A (ko) 2022-09-01
US20230055657A1 (en) 2023-02-23
CN114929219A (zh) 2022-08-19
TW202135812A (zh) 2021-10-01
WO2021127483A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
MX2020013116A (es) Sales y cristales novedosos.
MX2025004371A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4- tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
CO5570677A2 (es) Quinolinilpirrolopirazoles
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
RU2008146815A (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат
AR067024A1 (es) Metabolitos del inhibidor de janus quinasa (r)-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
GT201300308A (es) Combinación de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR061996A1 (es) Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR120859A1 (es) Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
MX2022009032A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
AR109809A1 (es) Métodos para el uso de agonistas de fxr

Legal Events

Date Code Title Description
FB Suspension of granting procedure